Novel CER Methods

Novel therapies have improved the survival of patients with cancer but have also increased treatment costs substantially. These therapies create an enormous financial burden for patients, their families, and society in general. Furthermore, there are several critical barriers to generating reliable evidence to guide treatment decision-making. First, there is a lack of head-to-head comparative evidence. Also, as the cancers progress, patients’ regimens can involve multiple lines of treatment. Thus, the relevant research question for clinical evidence often becomes not simply how one drug compares to another, but which treatment sequence may produce the best patient outcomes. This project will combine literature reviews, secondary data analyses, and simulation modeling to identify the optimal sequential treatments for advanced non-small cell lung cancer. By integrating practice patterns from real-world data with evidence from randomized controlled trials, our proposed framework could provide a new foundation for comparative effectiveness research.

Funding source: American Cancer Society

Principal Investigator: Shi-Yi Wang